AbbVie

Open: 165.27 Close: 164.17 Change: -1.1

What an AI can tell you about AbbVie before investing.

The game is changing. There is a new strategy to evaluate AbbVie fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, new, ABBV, manufacturing, facility, expect, job, and the …

Concept Map

Semantic Network

Stock Summary

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenos.

Today's Summary

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility. The project is expected to create more than 100 new jobs. The new investment is pegged to add 24,000 liters. The drugmaker is doubling down on cancer.

Today's News

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility. The project is expected to create more than 100 new jobs. The new investment is pegged to add 24,000 liters. AbbVie (ABBV) Is a Trending Stock: Facts to Know Before Betting on It Read full article on Zacks. AbbVie Inc (ABBV) stock has fallen -0.47% while the S&P 500 has risen 0.3% as of 12:10 PM on Thursday, Jan 25. ABBV has a conensus rating of Moderate Buy. The drugmaker is doubling down on cancer and neurology revenue as it seeks to replace falling revenue from its top sellers. AbbVie expects Botox market share to stay strong. Project Director II, R&D - Toxins at AbbVie. Responsibilities: Enterprise leader with primary responsibility to advance multiple research programs. AbbVie Inc (ABBV) stock has gained 0.63% while the S&P 500 has gained.02% as of 12:46 PM on Tuesday, Jan 23. ABBVie underwent analysis by 7 analysts in the last quarter. Senior Scientist I, Biologics Drug Product Development at AbbVie. Work cross-functionally and find solutions for business clients. AbbVie invests $223m to expand biologics manufacturing in singapore. This new investment will add more than 100 jobs and new biologic manufacturing capacity to Abbvies global network. Construction will commence immediately with facilities becoming operational in 2026.

Stock Profile

"AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois."

Keywords

Are looking for the most relevant information about AbbVie? Investor spend a lot of time searching for information to make investment decisions in AbbVie. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AbbVie are: AbbVie, new, ABBV, manufacturing, facility, expect, job, and the most common words in the summary are: abbvie, job, stock, market, get, direction, analyst, . One of the sentences in the summary was: The project is expected to create more than 100 new jobs. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #abbvie #job #stock #market #get #direction #analyst.